Brief: VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study Of VBI-1901 In Recurrent Glioblastoma
03/04/2024 13:37
April 3 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES PRESENTS ENCOURAGING EARLY TUMOR RESPONSE
DATA FROM
RANDOMIZED CONTROLLED PHASE 2B STUDY OF VBI-1901 IN RECURRENT
GLIOBLASTOMA
* VBI VACCINES INC - ADDITIONAL INTERIM DATA EXPECTED
MID-YEAR AND
YEAR-END 2024
Source text for Eikon: ID:nBw1NbFKJa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55